Jolly Good/Teijin Pharma develop VR digital therapeutics for depression
pharmaphorum
APRIL 26, 2021
Technology firm Jolly Good and Teijin Pharma have begun a partnership to develop virtual reality digital therapeutics (VR DTx) for major depressive disorder. The partnership will be based on Jolly Good’s technology and Teijin’s strategic expertise, the companies said.
Let's personalize your content